Ernexa Therapeutics Preclinical Validation and Stock Reaction
On 15 July 2026, Ernexa Therapeutics (NASDAQ:ERNA) saw its shares climb roughly 30% after the company released independent preclinical validation data for its lead cell‑therapy candidate, ERNA‑101, in ovarian cancer models.
The validation was performed by an independent contract research organization, which reproduced earlier findings generated at The University of Texas Anderson Cancer Center. In the larger study, ERNA‑101 combined with anti‑PD‑1 therapy achieved complete tumor clearance and long‑term survival in 10 of 15 treated animals, representing a 67% success rate. By contrast, none of the 45 animals receiving ERNA‑101 alone, anti‑PD‑1 alone, or no treatment exhibited complete tumor clearance or durable survival.
The preclinical work employed an immunocompetent ID8luc‑ova syngeneic ovarian cancer model, with tumor burden monitored through bioluminescence imaging to confirm treatment response and complete clearance.
Earlier investigations demonstrated that ERNA‑101 selectively homes to ovarian tumors and delivers an engineered IL‑7/IL‑15 fusion cytokine directly into the tumor micro‑environment, thereby enhancing infiltration of cancer‑fighting T cells that are typically excluded from the tumor.
Ernexa, which develops cell‑based therapies for advanced cancer and autoimmune disease, cited the third‑party validation as a key milestone ahead of its planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of a first‑in‑human Phase 1 clinical trial in the fourth quarter of 2026.